|
||
| |||||||
|
|
Paris, September 4, 2007 -
BioAlliance Pharma SA (Euronext Paris: FR0010095596 - BIO), a specialty
pharmaceutical company focused on the development of innovative therapeutics
targeting cancer, HIV, opportunistic infections and drug resistance,
announced today the launch of its first drug, Loramyc(R), on the French
market.
BioAlliance Pharma is the first biotech
company in France to have successfully managed the whole process of bringing
an academic innovation out of the lab, through R&D and onto the market.
Loramyc(R) is available on the French
market as of today at pharmacies and healthcare establishments, following
the official publication of its approval for use in hospitals as well as
details of reimbursement by French health authorities.
Loramyc(R) is a drug specifically
developed for Oropharyngeal Candidiasis in immunodepressed patients, who
frequently suffer an associated mucositis. It offers an optimized
anti-fungal treatment with the same level of activity as systemic therapies,
with the advantage that it specifically targets the mouth and the oropharynx.
The new therapeutic approach uses an
innovative delivery system based on a mucoadhesive buccal tablet. This
ensures an early and extended release of the active component at the site of
the infection, with only one dose per day.
"Our team of scientific sales
representatives report that hospital oncology and infection specialists have
shown a lot of interest in Loramyc(R), which responds to an unmet medical
need," said Florence Dupre, VP Sales & Marketing at BioAlliance Pharma.
"This launch is a key step for
BioAlliance Pharma and marks the first phase in our international
deployment. In fact, the agreements concluded this year are enabling us to
build a stronger market presence with Loramyc(R) in Europe, through our
SpeBio Joint Venture, and in the US, through our licensing partnership with
Par Pharmaceutical," said Dominique Costantini, President and CEO of
BioAlliance Pharma.
About BioAlliance Pharma:
BioAlliance Pharma SA (Euronext Paris:
BIO) is a specialty pharmaceutical company focused on the development and
commercialization of innovative therapeutics targeting drug resistance in
cancer, HIV, and opportunistic infections.
The Company is conducting clinical
development of three innovative products. Two products are based on the
Lauriad(R) mucoadhesive technology, which allows an early and prolonged
release of therapeutic agents at the site of the disease: one authorized
product in France and two clinical international phase III trials ongoing (Loramyc(R)
and aciclovir Lauriad(R)). One product is based on the Transdrug(R)
nanoparticle technology designed specifically for intracellular targeting:
one international phase III trial ongoing on primary liver cancer
(doxorubicin Transdrug(R)). The company develops also a New Entities program
focused on new targets in oncology and HIV. The Company has concluded two
strategic partnerships in 2007 to sell its Loramyc(R) product in Europe and
in the US.
Disclaimer
This communication expressly or
implicitly contains certain forward-looking statements concerning
BioAlliance Pharma SA and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause
the actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. BioAlliance Pharma SA is providing this communication as of this
date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or otherwise.
For a discussion of risks and
uncertainties which could cause actual results, financial condition,
performance or achievements of BioAlliance Pharma SA to differ from those
contained in the forward-looking statements please refer to the Risk Factors
(Facteurs de Risque) section of the reference document approved by the AMF
on 6 April 2007 under the number R. 07-031, which is available on the AMF
website
www.amf-france.org
or BioAlliance Pharma S.A.'s website
www.bioalliancepharma.com.
--
For further information, please
contact:
Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100
|
|
| ||||||||
